240 results about "Depressed - symptom" patented technology

The invention describes methods of treating depression comprising administering a TNFα antibody, such as a human TNFα antibody. The invention also provides a method for treating depression comprising inhibiting TNFα activity in a subject suffering from depression by systemically administering to the subject a human anti-TNFα antibody, or an antigen-binding portion thereof, such that depression is treated. Also described is a method for the treatment or alleviation of depression or other affective disorders comprising administering an amount of an anti-inflammatory agent effective to treat or alleviate depression or other affective disorder to a subject in need thereof, wherein said anti-inflammatory agent down-regulates peripheral cytokine levels to thereby treat or alleviate depression or other affective disorder.

The invention discloses novel application of tetrandrine in preparation of a drug for prevention, alleviation and/or treatment of depression. A result of a test shows that tetrandrine has obvious anti-depression curative effects, can produce effects fast and has few toxic and side effects, and thus is a safe, efficient and stable anti-depression drug of which a preparation process is simple. Therefore, tetrandrine is suitable for industrialized production and is easy to be popularized. The invention provides a novel drug source for prevention and treatment of depression and its concurrent diseases, disorder or illnesses.

The present invention relates to a method for the treatment of depression comprising administering a therapeutically effective amount of gaboxadol to a patient, wherein the level of one or more inflammatory markers in said patient is increased or abnormal. The present invention also relates to a method for the treatment of stress-mediated depression comprising administering a therapeutically effective amount of gaboxadol to a patient, wherein the level of one or more inflammatory markers is increased or abnormal in said patient. The present invention also relates to a method for the treatment of depression or the amelioration of one or more depressive symptoms comprising administering a therapeutically effective amount of gaboxadol to a patient, wherein the clinical presentation of one or more symptoms of depression are the physiological effect of a general medical condition. Furthermore the present also relates to a method for testing the therapeutic effectiveness of a compound in the treatment of depression or reducing the symptoms of depression comprising measuring the amount of one or more inflammatory markers in a sample from a patient before said compound is administered to the patient and comparing with the amount of said one or more inflammatory markers in a sample from the same patient after administration of said compound to the patient.

Provided herein are, inter alia, methods for identifying subjects suffering from depression that will respond to treatment with an antidepressant.

Disclosed herein are novel assays, systems and kits for selecting a treatment regimen for a subject with depression by identifying at least one nucleic acid polymorphism, e.g., but not limited to, at the MTHFR, MTR, or MTRR locus, and/or determining expression levels of peripheral biomarkers (e.g., SAM, SAH, and 4-HNE) in a test sample from a human subject. These biomarkers can be used to determine the effectiveness of treating a depressed subject with a folate-containing compound (alone or as an adjunct to an antidepressant). Additionally, these biomarkers can be used to select an appropriate treatment regimen for subjects with treatment-resistant depression (e.g., resistant to at least one selective serotonin reuptake inhibitor). Methods and compositions for treating a subject with depression and/or determining or improving the effectiveness of an antidepressant drug taken by a subject are also provided herein.

The invention provides a use of a blood metabolism marker and a depression detecting kit. The blood metabolism marker can be used for preparing a reagent or an apparatus for diagnosing depression, for example a kit which comprises standard pure liquor with concentration being 10mg/ml of the metabolism marker, 13C stable isotope internal standard liquor, methanol-aqueous solution with a volume ratio being 1 to 1, one analytical chromatographic column and quality control standard serum; the kit can be used for accurately measuring content of 14 screened metabolism markers in blood, and is utilized for early diagnosing the depression with specificity being 86.8%, sensitivity being 96.8% and accuracy rate being 93.0%, so that the diagnosis of the depression does not depend on a questionnaire completely for subjective judgment, and therefore, the diagnosis accuracy is greatly improved.

The invention relates to a 5-HTT gene 13C/T polymorphism site genotype used for forecasting an individual depression sickness degree as well as the sickness degree of the core symptom of the depression, forecasting the effect of an antidepressant as well as the usage, the method and the reagent box of the effect of the antidepressant on the core symptom of the depression; wherein, when the 5-HTT gene 13C/T polymorphism site genotype is of 13TT homozygous type, the individual depression sickness degree and the sickness degree of the core symptom of the depression are forecasted to be more serious; the effect after taking the antidepressant is better; the effect of the antidepressant to the core symptom of the depression is better; when the 5-HTT gene 13C/T polymorphism site genotype is of 13CC homozygous type or 13CT heterozygote type, the individual depression sickness degree and the sickness degree of the core symptom of the depression are forecasted to be lighter; the effect after taking the antidepressant is poorer; the effect of the antidepressant to the core symptom of the depression is poorer.

Disclosed is a method of treating Psychotic Depression, Suicidal Ideation, Disruptive Mood Dysregulation Disorder, Persistent Depressive Disorder (Dysthymia), Premenstrual Dysphoric Disorder, Substance/Medication-Induced Depressive Disorder, Depressive Disorder Due to Another Medical Condition, Other Specified Depressive Disorder, Unspecified Depressive Disorder, Separation Anxiety Disorder, Selective Mutism, Specific Phobia, Social Anxiety Disorder (Social Phobia), Panic Disorder, Panic Attack (Specifier), Agoraphobia, Generalized Anxiety Disorder, Substance/Medication-Induced Anxiety Disorder, Anxiety Disorder Due to Another Medical, Other Specified Anxiety Disorder, Unspecified Anxiety Disorder, or fatigue, the method including administering a pharmaceutical composition containing an effective amount of an active agent, wherein the active agent is purified (2R,6R)-hydroxynorketamine, purified (2S,6S)-hydroxynorketamine, or a combination thereof, or a pharmaceutically acceptable saltthereof, together with a pharmaceutically acceptable carrier to a patient in need of such treatment.

Bombesin receptor antagonists are provided which are compounds of formula (I) or pharmaceutically acceptable salts thereof: wherein j, k, l, m, n, q, r, Ar, Ar<1>, R<1>, R<2>, R<3>, R<4>, R<5>, R<6 >and X are as defined in the description. The compounds of the invention have an affinity for the BB1 receptor and some of them also have affinity for the BB2 receptor. Accordingly they may be useful for the diagnosis, prevention, or treatment of male and female sexual dysfunction. They can also be used in the diagnosis, prevention or treatment of anxiety and panic disorders, social phobia, depression, psychoses, sleeping disorders, memory impairment, pulmonary hypertension, lung repair and lung development disorders, cancer including prostate cancer and pancreatic cancer, hepatic porphyria, gastrointestinal secretory disturbances, gastrointestinal disorders including colitis, Crohn's disease and inflammatory bowel disease, emesis, anorexia, pain, seasonal affective disorders, feeding disorders or pruritus.

The invention discloses a pharmaceutical composition for treating and preventing depression and a preparation method of the pharmaceutical composition. The composition consists of radix bupleuri extract, Chinese angelica extract and white atractylodes rhizome extract. According to the pharmacological experiment results, the pharmaceutical composition can be used for obviously reducing dead time in a mouse forced swimming test and a mice hanging test, remarkably increasing chronic temperature and the weight and the sweet water eccentricity of an unpredictable depression model, and has an obvious anti-depression effect which can reach or exceed that of the existing clinical common anti-depression drugs.

The invention discloses a pharmaceutical composition with the effects of hypnosis, anti-depression and anti-anxiety, and belongs to the traditional Chinese medicine field. The pharmaceutical raw materials of the pharmaceutical composition are: 6 to 40 parts by weight of Szechuan lovage rhizome and 10 to 40 parts by weight of pinellia tuber which are taken as monarch drugs; and 3 to 20 parts by weight of cape jasmine fruit or 1 to 15 parts by weight of golden thread which are taken as ministcrial drugs. The pharmaceutical composition can be prepared into any common preparation form for internal usage. The different adjuvant drugs or guide drugs can be added on the basis of the monarch drugs and the ministcrial drugs according to the different individual differences, so as to play the better efficacy. The pharmaceutical composition of the invention has the effects of hypnosis, anti-depression and anti-anxiety, the efficacy for the treatment of insomnia, depression and anxiety disorder is exact, the onset of action is fast, and the pharmaceutical composition can also be used for the treatment of insomnia, melancholia, headache, palpitation and other diseases of the traditional Chinese medicine.

The invention provides a depression intestinal biomarker and application thereof. The intestinal biomarker is selected from one or more of intestinal microorganisms and excrement metabolites. The invention further provides a kit for diagnosing depression and a screening method for screening the biomarker for depression.

The invention discloses applications of a stilbene compounds for preparing medicaments for preventing and treating depression, wherein the stilbene compounds can be used as an effective active component to prepare the medicaments for preventing and treating depression. The stilbene compounds are mixtures containing ore or both of piceatannol or piceatannol 3'-O-beta-D-glucopyranoside, and used in the medicaments for preventing and treating endogenous depression, and/or reactive depression, and/or masked depression, and/or depression using learning difficulty as a characteristic; and/or secondary depression caused by medicaments, and/or secondary depression caused by body diseases, and/or postnatal depression, and/or involutional melancholia, and/or depressive neurosis. By a Konmin mouse tail suspension test, a swimming force test and a chronic stress sucrose preference determination experiment, the stilbene compounds can substantially raises disappointed time of mouse tail suspension and motionless time of forced swimming, has substantial resistant effect for interest deprivation symptom caused by chronic stress, and has a substantial antidepressant effect.

The invention discloses a depression symptom information evaluation method, which analyzes interview contents of a visitor and a psychologist, fuses voice features and character embedding features ininterview audio and character translations, scores depression-related psychological scale corresponding to the visitor, and improves the evaluation accuracy under the condition of not limiting the interview contents. According to the invention, an objective depression auxiliary evaluation method and rapid, effective and economic depression symptom self-evaluation can be provided for psychologists.

This invention provides methods for determining whether an agent, known to upregulate the sonic hedgehog pathway, increases brain progenitor cell division in a subject. Furthermore, this invention provides methods for treating anxiety, depression, a cognitive disorder or a neuro-degenerative disorder or inhibiting the onset of anxiety, depression or a cognitive disorder by administering to an afflicted subject a therapeutically or prophylactically effective amount of the agent known to upregulate the sonic hedgehog pathway. Finally, this invention provides methods for treating anxiety, depression, a cognitive disorder or a neuro-degenerative disorder or inhibiting the onset of anxiety, depression or a cognitive disorder by administering to an afflicted subject a therapeutically or prophylactically effective amount of Hh-Ag 1.1, Hh-Ag 1.2, Hh-Ag 1.3, or a derivative of Hh-Ag 1.1, Hh-Ag 1.2 or Hh-Ag 1.3.

The present invention provides devices and methods for treating depression in a patient, comprising administering to the patient in need of the treatment a therapeutically effective amount of esketamine. In some embodiments, the depression is major depressive disorder or treatment resistant depression. In other embodiments, the therapeutically effective amount is clinically proven safe and/or effective. Also provided are methods to mitigate the risk or misuse or abuse of esketamine, instructions for use of the esketamine product, and methods for selling a drug product containing esketamine.

A system, method and kit for reminiscence therapy on an individual and group setting to treat depression and other disorders based on timing and application of reminiscence therapy using the compositions of one or more audio and visual elements configured to constructively interact with the individual's autobiographical memory components to stimulate memory components of the life of the individual with dementia.